Literature DB >> 29784663

Involvement of Nicotinic Receptor Subtypes in the Behavioral Effects of Nicotinic Drugs in Squirrel Monkeys.

Sarah L Withey1, Michelle R Doyle1, Jack Bergman1, Rajeev I Desai2.   

Abstract

Evidence suggests that the α4β2, but not the α7, subtype of the nicotinic acetylcholine receptor (nAChR) plays a key role in mediating the behavioral effects of nicotine and related drugs. However, the importance of other nAChR subtypes remains unclear. The present studies were conducted to examine the involvement of nAChR subtypes by determining the effects of selected nicotinic agonists and antagonists in squirrel monkeys either 1) responding for food reinforcement or 2) discriminating the nicotinic agonist (+)-epibatidine (0.001 mg/kg) from vehicle. In food-reinforcement studies, nicotine, (+)-epibatidine, varenicline and cytisine all produced dose-dependent decreases in rates of food-maintained responding. The rate-decreasing effects of nicotine were antagonized by mecamylamine (nonselective), not appreciably altered by dihydro-β-erythroidine (α4β2 selective), and exacerbated by the nicotinic partial agonists, varenicline and cytisine. Results from discrimination studies show that non-nicotinic drugs did not substitute for (+)-epibatidine, and that except for lobeline, the nicotinic agonists produced either full [(+)-epibatidine, (-)-epibatidine, and nicotine] or partial (varenicline, cytisine, anabaseine, and isoarecolone) substitution for (+)-epibatidine. In interaction studies with antagonists differing in selectivity, (+)-epibatidine discrimination was substantively antagonized by mecamylamine, slightly attenuated by hexamethonium (peripherally restricted) or dihydro-β-erythroidine, and not altered by methyllycaconitine (α7 selective). Varenicline and cytisine enhanced (+)-epibatidine's discriminative-stimulus effects. Correlational analysis revealed a close correspondence between relative behavioral potencies of nicotinic agonists in both studies and their published relative binding affinities at α4β2 and α3β4, but not α7 nAChR, subtypes. Collectively, these results are consistent with the idea that the α4β2 and α3β4, but not α7 nAChR subtypes play a role in the behavioral effects of nicotinic agonists.
Copyright © 2018 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29784663      PMCID: PMC6053592          DOI: 10.1124/jpet.118.248070

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  77 in total

1.  Effects of isoarecolone, a nicotinic receptor agonist in rodent models of nicotine dependence.

Authors:  Mohammed Shoaib
Journal:  Psychopharmacology (Berl)       Date:  2006-08-24       Impact factor: 4.530

Review 2.  A novel mechanism of action and potential use for lobeline as a treatment for psychostimulant abuse.

Authors:  Linda P Dwoskin; Peter A Crooks
Journal:  Biochem Pharmacol       Date:  2002-01-15       Impact factor: 5.858

3.  Differential modulation of brain nicotinic acetylcholine receptor function by cytisine, varenicline, and two novel bispidine compounds: emergent properties of a hybrid molecule.

Authors:  Can Peng; Clare Stokes; Yann S Mineur; Marina R Picciotto; Chengju Tian; Christoph Eibl; Isabelle Tomassoli; Daniela Guendisch; Roger L Papke
Journal:  J Pharmacol Exp Ther       Date:  2013-08-19       Impact factor: 4.030

4.  Effects of kappa opioids on schedule-controlled behavior of squirrel monkeys.

Authors:  J Bergman; P H Warren
Journal:  J Pharmacol Exp Ther       Date:  1989-03       Impact factor: 4.030

5.  Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid.

Authors:  H Rollema; L K Chambers; J W Coe; J Glowa; R S Hurst; L A Lebel; Y Lu; R S Mansbach; R J Mather; C C Rovetti; S B Sands; E Schaeffer; D W Schulz; F D Tingley; K E Williams
Journal:  Neuropharmacology       Date:  2006-12-08       Impact factor: 5.250

6.  5-Iodo-A-85380, an alpha4beta2 subtype-selective ligand for nicotinic acetylcholine receptors.

Authors:  A G Mukhin; D Gündisch; A G Horti; A O Koren; G Tamagnan; A S Kimes; J Chambers; D B Vaupel; S L King; M R Picciotto; R B Innis; E D London
Journal:  Mol Pharmacol       Date:  2000-03       Impact factor: 4.436

7.  Nicotinic binding sites in rat and mouse brain: comparison of acetylcholine, nicotine, and alpha-bungarotoxin.

Authors:  M J Marks; J A Stitzel; E Romm; J M Wehner; A C Collins
Journal:  Mol Pharmacol       Date:  1986-11       Impact factor: 4.436

8.  Role of training dose in discrimination of nicotine and related compounds by rats.

Authors:  I P Stolerman; H S Garcha; J A Pratt; R Kumar
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

Review 9.  The "stop" and "go" of nicotine dependence: role of GABA and glutamate.

Authors:  Manoranjan S D'Souza; Athina Markou
Journal:  Cold Spring Harb Perspect Med       Date:  2013-06-01       Impact factor: 6.915

Review 10.  Epibatidine: impact on nicotinic receptor research.

Authors:  Małgorzata Dukat; Richard A Glennon
Journal:  Cell Mol Neurobiol       Date:  2003-06       Impact factor: 5.046

View more
  7 in total

1.  Nicotine promotes the utility of short-term memory during visual search in macaque monkeys.

Authors:  Ryo Sawagashira; Masaki Tanaka
Journal:  Psychopharmacology (Berl)       Date:  2022-07-08       Impact factor: 4.415

2.  Nicotinic aspects of the discriminative stimulus effects of arecoline.

Authors:  Gail Winger
Journal:  Behav Pharmacol       Date:  2021-10-01       Impact factor: 2.277

3.  Enhancement of Opioid Antinociception by Nicotine.

Authors:  Fernando Barreto de Moura; Sarah Louise Withey; Jack Bergman
Journal:  J Pharmacol Exp Ther       Date:  2019-09-16       Impact factor: 4.030

4.  Enhancement of Opioid Antinociception by Nicotinic Ligands.

Authors:  Fernando B de Moura; Jack Bergman
Journal:  J Pharmacol Exp Ther       Date:  2021-01-13       Impact factor: 4.030

5.  Effects of nicotinic antagonists on working memory performance in young rhesus monkeys.

Authors:  Nicholas A Upright; Mark G Baxter
Journal:  Neurobiol Learn Mem       Date:  2021-08-20       Impact factor: 3.109

6.  Anatabine, Nornicotine, and Anabasine Reduce Weight Gain and Body Fat through Decreases in Food Intake and Increases in Physical Activity.

Authors:  Patricia E Grebenstein; Paige Erickson; Martha Grace; Catherine M Kotz
Journal:  J Clin Med       Date:  2022-01-18       Impact factor: 4.241

7.  The discriminative stimulus effects of epibatidine in C57BL/6J mice.

Authors:  Fernando B de Moura; Takato Hiranita; Lance R McMahon
Journal:  Behav Pharmacol       Date:  2020-09       Impact factor: 2.277

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.